...
首页> 外文期刊>Journal of chemical information and modeling >Protein Flexibility in Docking-Based Virtual Screening: Discovery of Novel Lymphoid-Specific Tyrosine Phosphatase Inhibitors Using Multiple Crystal Structures
【24h】

Protein Flexibility in Docking-Based Virtual Screening: Discovery of Novel Lymphoid-Specific Tyrosine Phosphatase Inhibitors Using Multiple Crystal Structures

机译:在基于坞站的虚拟筛选中的蛋白质灵活性:使用多个晶体结构的新型淋巴特异性酪氨酸磷酸酶抑制剂的发现。

获取原文
获取原文并翻译 | 示例
           

摘要

Incorporating protein flexibility is a major challenge for docking-based virtual screening. With an increasing number of available crystal structures, ensemble docking with multiple protein structures is an efficient approach to deal with protein flexibility. Herein, we report the successful application of a docking-based virtual screen using multiple crystal structures to discover novel inhibitors of lymphoid-specific tyrosine phosphatase (LYP), a potential drug target for autoimmune diseases. The appropriate use of multiple protein structures allowed a better enrichment than a single structure in the recovery of known inhibitors. Subsequently, an optimal ensemble of LYP structures was selected and used in docking-based virtual screening. Eight novel LYP inhibitors (IC50 ranging from 7.95 to 56.6 mu M) were identified among 23 hit compounds. Further studies demonstrated that the most active compound B15 possessed some selectivity over other protein phosphatases and could effectively up-regulate TCR (T cell receptor)-mediated signaling in Jurkat T cells. These novel hits not only provided good starting points for the development of therapeutic agents useful in autoimmune diseases but also demonstrated the advantages of choosing an appropriate ensemble of protein structures in docking-based virtual screening over using a single protein conformation.
机译:整合蛋白质的灵活性是基于对接的虚拟筛选的主要挑战。随着可用晶体结构数量的增加,具有多种蛋白质结构的整体对接是处理蛋白质柔韧性的有效方法。在本文中,我们报道了使用多种晶体结构的基于对接的虚拟屏幕的成功应用,以发现淋巴样酪氨酸磷酸酶(LYP)的新型抑制剂,后者是自身免疫性疾病的潜在药物靶标。在回收已知抑制剂方面,适当使用多种蛋白质结构比单一结构可实现更好的富集。随后,选择了LYP结构的最佳集合,并用于基于对接的虚拟筛选。在23种命中化合物中鉴定出八种新型LYP抑制剂(IC50为7.95至56.6μM)。进一步的研究表明,活性最高的化合物B15对其他蛋白质磷酸酶具有一定的选择性,并且可以有效地上调Jurkat T细胞中TCR(T细胞受体)介导的信号传导。这些新颖的命中方法不仅为开发可用于自身免疫性疾病的治疗剂提供了良好的起点,而且证明了在基于对接的虚拟筛选中使用单个蛋白质构象选择合适的蛋白质结构集合的优势。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号